InfanDx AG, a diagnostics company specialized in the development of biomarker-based tests, announced today that it has been granted U.S. Patent 141013 US, titled „Method and use of metabolites for the diagnosis and differentiation of neonatal encephalopathy”.
Cologne/Germany, 09 January 2020. InfanDx AG, a diagnostics company specialized in the development of biomarker-based tests, announced today that it has been granted U.S. Patent 141013 US, titled „Method and use of metabolites for the diagnosis and differentiation of neonatal encephalopathy”. The United States Patent and Trademark Office approved the comprehensive patent, which covers the diagnosis of neonatal encephalopathy using biomarkers, at the end of December 2019. This is the second U.S. patent for the HypoxE-test®, following the patent for the diagnosis of perinatal asphyxia. In the EU, InfanDx had already been awarded patent protection for both indications.
The HypoxE-test® is based on metabolomic biomarkers to rapidly diagnose brain damage, which can result from oxygen deficit during delivery (asphyxia neonatorum). This way, affected newborns can be treated in time with an established therapeutic intervention, hypothermia, which limits or completely prevents permanent damage. However, this treatment has to be initiated within six hours after birth. InfanDx aims to offer the first test worldwide to reliably diagnose affected babies within this time window.
“We are excited that we have now received a particularly clear and broad protection for our novel test also in the U.S. as well. Despite the difficult legal situation for biomarker-based tests following the so-called Prometheus ruling in the U.S., we have managed to obtain two essential patents for our test here. Receiving patent protection in such an important market clearly signals our innovative strength,” said Ron Meyer, CEO of InfanDx.
InfanDx plans to market the test as a user-friendly disposable test cartridge together with a dedicated diagnostic device. This will allow for a rapid and easy diagnosis directly in the delivery room. Of the 125 million newborns worldwide each year, 5 - 10 % are at risk to have suffered perinatal asphyxia.
For further information, please contact:
InfanDx AG
Ron Meyer (CEO)
T: +49 (0) 221 29271401
info@infandx.com
Media contact
MC Services AG
Kaja Skorka, Dr. Regina Lutz
T: +49 (0) 89 210 228 25
Kaja.Skorka@mc-services.eu
About InfanDx
InfanDx AG is a privately held company established in 2010 in Cologne, Germany. The company focuses on the development of a new generation of diagnostic tests based on biomarkers derived from an integrated combination of genomics, proteomics and particularly metabolomics research. Lead product candidate is the InfanDx HypoxE-test® for rapid and reliable diagnosis of perinatal asphyxia (oxygen deficit during birth), a major cause for brain injury often followed by life-long disability. Treatment is available only if initiated within six hours from birth. As first in class, the InfanDx HypoxE-test® will be able to deliver reliable results within this time frame. The test itself and its accompanying diagnostic instrument are currently in clinical development. Other biomarker-based diagnostics are in development. For more information, please visit: http://www.infandx.de
